|Videos|March 3, 2022

Combination neoadjuvant nivolumab/gemcitabine-cisplatin is efficacious in pathologically downstaging MIBC

“The complete response rates were 49%, which is quite impressive compared to historical controls,” says Shilpa Gupta, MD.

In this video, Shilpa Gupta, MD, discusses the background and findings of the study, “Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Gupta is the director of genitourinary oncology at Cleveland Clinic in Ohio.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Related Content

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
Virtual Event

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

View more
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

View more